Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients
This randomized pilot clinical trial studies exercise intervention in improving quality of life and exercise capacity and reducing inflammation and oxidative stress in patients with lung cancer and their support persons. Exercise therapy may help improve quality of life, may increase exercise capacity, and may reduce inflammation and oxidative stress in patients with lung cancer and their supporters.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
Plus 2 other study approaches.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Nov 18, 2019 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Supportive Care
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- University of Wisconsin, Madison
- Interventions being studied
- Behavioral: exercise intervention; Procedure: standard follow-up care; Procedure: quality-of-life assessment; Other: laboratory biomarker analysis
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- LUNG CANCER PATIENTS: A confirmed diagnosis of any stage lung cancer (non-small cell lung cancer \[NSCLC\] or small cell lung cancer \[SCLC\])
- LUNG CANCER PATIENTS: Can be receiving any type of treatment (chemotherapy, radiation therapy, both or neither) are eligible
- LUNG CANCER PATIENTS: Able to understand and read in English sufficiently to adequately complete informed consent to participate and to complete the questionnaires
- LUNG CANCER PATIENTS: For patients treated with curative intent, and who have not relapsed, they must be within 1 year of their diagnosis of lung cancer (determined by date of diagnostic pathology sample)
- SUPPORT PERSONS: Able to understand and read in English sufficiently to adequately complete informed consent to participate and to complete the questionnaires
- LUNG CANCER PATIENTS: Symptomatic heart disease including congestive heart failure or arrhythmia
- LUNG CANCER PATIENTS: Documented myocardial infarction in the last three months
- LUNG CANCER PATIENTS: Central nervous system (CNS) metastases that results in impaired ability to participate in an exercise program at the discretion of the study physician
- LUNG CANCER PATIENTS: Any psychological or physical disease that would impair or prevent participation in an exercise program at the discretion of the study physician
- LUNG CANCER PATIENTS: Cognitive or reading impairments that would preclude them from completing questionnaires
- LUNG CANCER PATIENTS: Current participation in an exercise program
- SUPPORT PERSONS: Symptomatic heart disease including congestive heart failure or arrhythmia
- SUPPORT PERSONS: Documented myocardial infarction in the last three months
- SUPPORT PERSONS: Cognitive or reading impairments that would preclude them from completing questionnaires
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- UW Health Oncology - 1 South ParkMadison, Wisconsin
- University of Wisconsin, MadisonMadison, Wisconsin
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 18, 2019. Always confirm current availability with the study team.